Figure 5.
Epitope mapping by pairwise binding experiments and ligand competition. (a) Antibodies BCD090-P1 and BCD090-M2 bind simultaneously to ErbB3 ECD; (b) the same result is for BCD090-P1 versus BCD090-M456; (c) BCD090-M2 and BCD090-M456 attack the overlapping epitopes as seen from the lack of simultaneous binding; (d) BCD090-P1 does not block the binding of natural ErbB3 ligand, heregulin; (e) saturation of ECD with BCD090-M2 completely abolishes ligand binding.